Open Access

LACTB and LC3 could serve as potential biomarkers of gastric cancer to neoadjuvant chemotherapy with oxaliplatin plus S‑1

  • Authors:
    • Fang Yang
    • Zhiqiang Yan
    • Wei Nie
    • Zeying Liu
    • Xingzhen Cheng
    • Wei Wang
    • Chunyan Shao
    • Gui Fu
    • Yanni Yu
  • View Affiliations

  • Published online on: April 13, 2021     https://doi.org/10.3892/ol.2021.12731
  • Article Number: 470
  • Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study investigated and evaluated the correlation between the expression of LACTB and LC3 and the clinical outcomes of patients with advanced gastric cancer treated with oxaliplatin plus S‑1 neoadjuvant chemotherapy (NACT). A total of 51 patients with advanced gastric cancer underwent NACT treatment between June 2015 and June 2017. Pathomorphological changes in gastric cancer were analyzed by H&E staining. The expression level and subcellular localization of LACTB and LC3 in paraffin‑embedded biopsies were detected by immunohistochemistry and immunofluorescence. The mRNA and protein expression of LACTB were investigated by reverse transcription quantitative polymerase chain reaction and Western blotting, respectively. Statistical analysis was performed to determine the association between the expression of LACTB and LC3 and clinical chemotherapy efficacy of NACT for gastric cancer. Among the 51 patients, 3 (5.88%), 27 (52.94%), 13 (25.49%) and 8 (15.69%) displayed complete remission, partial remission, stable disease and progressive disease, respectively. The rate of decreased LACTB expression was 68.6%, while the rate of increased LC3 expression was 60.8%. Furthermore, there was a significant negative correlation between the expression of LACTB and that of LC3 following NACT (P<0.001). High expression of LC3 (P<0.01) and low expression of LACTB (P<0.01) were associated with a poor response of patients with advanced gastric cancer to NACT. In conclusion, the expression of LACTB and LC3 may serve as a promising novel biomarker for determining the prognosis of patients with advanced gastric cancer receiving NACT, while its potential clinical significance requires further elucidation.
View Figures
View References

Related Articles

Journal Cover

June-2021
Volume 21 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yang F, Yan Z, Nie W, Liu Z, Cheng X, Wang W, Shao C, Fu G and Yu Y: LACTB and LC3 could serve as potential biomarkers of gastric cancer to neoadjuvant chemotherapy with oxaliplatin plus S‑1. Oncol Lett 21: 470, 2021
APA
Yang, F., Yan, Z., Nie, W., Liu, Z., Cheng, X., Wang, W. ... Yu, Y. (2021). LACTB and LC3 could serve as potential biomarkers of gastric cancer to neoadjuvant chemotherapy with oxaliplatin plus S‑1. Oncology Letters, 21, 470. https://doi.org/10.3892/ol.2021.12731
MLA
Yang, F., Yan, Z., Nie, W., Liu, Z., Cheng, X., Wang, W., Shao, C., Fu, G., Yu, Y."LACTB and LC3 could serve as potential biomarkers of gastric cancer to neoadjuvant chemotherapy with oxaliplatin plus S‑1". Oncology Letters 21.6 (2021): 470.
Chicago
Yang, F., Yan, Z., Nie, W., Liu, Z., Cheng, X., Wang, W., Shao, C., Fu, G., Yu, Y."LACTB and LC3 could serve as potential biomarkers of gastric cancer to neoadjuvant chemotherapy with oxaliplatin plus S‑1". Oncology Letters 21, no. 6 (2021): 470. https://doi.org/10.3892/ol.2021.12731